Nu-Med Plus (NUMD) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 11, 2023
Document Information Line Items
Entity Registrant Name	NU-MED PLUS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		81,348,469
Amendment Flag	false
Entity Central Index Key	0001543637
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54808
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	45-3672530
Entity Address, Address Line One	640 Belle Terre Rd Building 2 E
Entity Address, City or Town	Port Jefferson
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11777
City Area Code	(631)
Local Phone Number	403-4337
Title of 12(b) Security	None
Entity Interactive Data Current	Yes

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash	$ 29,957	$ 73,195
Accounts receivable
Prepaid expenses	6,590	6,350
Total current assets	36,547	79,545
Long-term assets
Property and equipment, net
Total assets	36,547	79,545
Current liabilities
Accounts payable	14,239	7,192
Accounts payable – related party	34,378	34,378
Note payable	100,000	100,000
Accrued expenses	3,479	1,000
Total current liabilities	152,096	142,570
Long-term liabilities
Total liabilities	152,096	142,570
Commitments and contingencies
Stockholders' deficit
Preferred stock; $0.001 par value; 10,000,000 authorized; no shares issued and outstanding
Common stock; $0.001 par value; 90,000,000 authorized; 81,348,469 and 81,348,469 shares issued and outstanding, as of June 30, 2023 and December 31, 2022, respectively.	81,349	81,349
Additional paid-in capital	9,555,087	9,555,087
Accumulated deficit	(9,751,985)	(9,699,461)
Total stockholders' deficit	(115,549)	(63,025)
Total liabilities and stockholders' deficit	$ 36,547	$ 79,545

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022	Oct. 19, 2011
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par or stated value per share (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares, issued	81,348,469	81,348,469
Common stock, shares, outstanding	81,348,469	81,348,469

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue
Operating expenses
General and administrative expense	6,573	11,238	12,990	14,199
Payroll expense		12,000		24,000
Rent expense	3,300	4,235	6,600	7,412
Professional and consulting fees	13,200	30,380	30,455	69,880
Depreciation expense		217		2,232
Total operating expenses	23,073	58,070	50,045	117,723
Operating Loss	(23,073)	(58,070)	(50,045)	(117,723)
Other income (expense)
Gain on sale of assets				3,000
Interest expense	(1,247)		(2,479)
Total other income (expense)	(1,247)		(2,479)	3,000
Net loss before income tax	(24,320)	(58,070)	(52,524)	(114,723)
Income tax expense
Net loss	$ (24,320)	$ (58,070)	$ (52,524)	$ (114,723)
Basic and diluted loss per share (in Dollars per share)	$ 0	$ 0	$ 0	$ (0.01)
Weighted average common shares outstanding - basic and diluted (in Shares)	81,348,469	79,348,469	81,348,469	79,348,469

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Basic and diluted loss per share (in Dollars per share)	$ 0	$ 0	$ 0	$ (0.01)
Weighted average common shares outstanding - basic and diluted (in Shares)	81,348,469	79,348,469	81,348,469	79,348,469

Statements of Stockholders_ Def

Statements of Stockholders’ Deficit (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated deficit	Total
Balance at Dec. 31, 2021		$ 79,349	$ 9,357,587	$ (9,569,294)	$ (132,358)
Balance (in Shares) at Dec. 31, 2021		79,348,469
Net loss				(56,653)	(56,653)
Balance at Mar. 31, 2022		$ 79,349	9,357,587	(9,625,947)	(189,011)
Balance (in Shares) at Mar. 31, 2022		79,348,469
Balance at Dec. 31, 2021		$ 79,349	9,357,587	(9,569,294)	(132,358)
Balance (in Shares) at Dec. 31, 2021		79,348,469
Net loss					(114,723)
Balance at Jun. 30, 2022		$ 79,349	9,357,587	(9,684,017)	(247,081)
Balance (in Shares) at Jun. 30, 2022		79,348,469
Balance at Mar. 31, 2022		$ 79,349	9,357,587	(9,625,947)	(189,011)
Balance (in Shares) at Mar. 31, 2022		79,348,469
Net loss				(58,070)	(58,070)
Balance at Jun. 30, 2022		$ 79,349	9,357,587	(9,684,017)	(247,081)
Balance (in Shares) at Jun. 30, 2022		79,348,469
Balance at Dec. 31, 2022		$ 81,349	9,555,087	(9,699,461)	(63,025)
Balance (in Shares) at Dec. 31, 2022		81,348,469
Net loss				(28,204)	(28,204)
Balance at Mar. 31, 2023		$ 81,349	9,555,087	(9,727.665)	(91,229)
Balance (in Shares) at Mar. 31, 2023		81,348,469
Balance at Dec. 31, 2022		$ 81,349	9,555,087	(9,699,461)	(63,025)
Balance (in Shares) at Dec. 31, 2022		81,348,469
Net loss					(52,524)
Balance at Jun. 30, 2023		$ 81,349	9,555,087	(9,751,985)	(115,549)
Balance (in Shares) at Jun. 30, 2023		81,348,469
Balance at Mar. 31, 2023		$ 81,349	9,555,087	(9,727.665)	(91,229)
Balance (in Shares) at Mar. 31, 2023		81,348,469
Net loss				(24,320)	(24,320)
Balance at Jun. 30, 2023		$ 81,349	$ 9,555,087	$ (9,751,985)	$ (115,549)
Balance (in Shares) at Jun. 30, 2023		81,348,469

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (52,524)	$ (114,723)
Adjustment to reconcile net income (loss) to net cash used in operating activities:
Depreciation		2,232
Gain on sale of equipment		(3,000)
Amortization of right of use asset		6,166
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses	(240)	(6,350)
Operating lease liability		(6,166)
Accounts payable	7,047	31,805
Accounts payable-related party		33,361
Accrued expense	2,479	42,000
Net cash used in operating activities	(43,238)	(14,675)
Cash flows from investing activities:
Proceeds from sale of equipment		3,000
Net cash provided by investing activities		3,000
Cash flows from financing activities
Proceeds from issuance of common stock
Net cash provided by financing activities
Net change in cash	(43,238)	(11,675)
Cash at beginning of period	73,195	11,675
Cash at end of period	29,957
Supplemental schedule of cash flow information
Cash paid for interest
Cash paid for income tax
Non-Cash Investing and Financing Activities
Common stock issued for subscription payable

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The recent COVID 19 Pandemic (“the Pandemic”) has had a dramatic effect on our business as well as the business of our contract developers. The wide-ranging effect on the world-wide business market has led to a closure or partial closure of firms we are relying on in our product development. As a result their work on our project has been slowed. While we cannot predict when the influence of the Pandemic will end, we trust businesses will be able to open and expand activities to their former levels and increase following a return to normal operations. a. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of Nu-Med Plus, Inc. (the “Company”). These financial statements are condensed and, therefore, do not include all disclosures normally required by accounting principles generally accepted in the United States of America. Therefore, these statements should be read in conjunction with the most recent annual consolidated financial statements of Nu-Med Plus, Inc. for the year ended December 31, 2022 included in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023. In particular, the Company’s significant accounting principles were presented as Note 1 to the Consolidated Financial Statements in that report. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying condensed consolidated financial statements and consist of only normal recurring adjustments. The results of operations presented in the accompanying condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023. b. Revenue Recognition The Financial Accounting Standards Board (“FSB”) issued new guidance for the recognizing and reporting of revenue in contracts with customers. The effective date for implementation for public companies was January 1, 2018. The new guidance established a five-step analysis to be followed when determining the recognition of revenue. 1. Identify the contract with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when, or as, the reporting organization satisfied a performance obligation. While the Company is an early-stage company with no revenue, at the time we begin to generate revenue the Company will recognize such revenue in conformity with the guidelines set forth by ASC 606. c. Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. d. Cash and Cash Equivalents The Company considers all deposit accounts and investment accounts with an original maturity of 90 days or less to be cash equivalents. The cash balance we currently have on deposit is within the limits for which the FDIC insures. e. Property and Equipment Property and equipment is stated at cost. Expenditure for minor repairs, maintenance, and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. Expenditures, exceeding $500, for new assets or that increase the useful life of existing assets are capitalized. Depreciation is computed using the straight-line method. The lives over which the property and equipment are depreciated are five to seven years. f. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB Accounting Standards Codification (“ASC”) Topic 820 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements), as follows: Level 1 - Quoted market prices in active markets for identical assets or liabilities; Level 2 - Inputs other than level one inputs that are either directly or indirectly observable; and Level 3 - Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. All cash, accounts payable and accrued liabilities are carried at cost, which approximates fair value due to the short-term nature of these financial instruments. Additionally, we measure certain financial instruments at fair value on a recurring basis. g. Earnings per Share The computation of earnings per share of common stock is based on the weighted average number of shares outstanding during the period of the financial statement. The company included -0- and -0- shares subscribed but unissued in its calculation of basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022, respectively. Diluted earnings per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. As of June 30, 2023 and 2022 there were -0- and -0-, respectively, potential dilutive shares that needed to be considered as common share equivalents. As of June 30, 2023 and 2022 there were no dilutive shares and the basic and diluted calculation is the same. Had there been dilutive shares they would have been excluded from the calculation for diluted earnings per share as there was a net loss and their inclusion in the calculation would be anti-dilutive. h. Concentrations and Credit Risk - i. Income Taxes Deferred taxes are provided on an asset and liability approach whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. j. Stock-based Compensation The Company, in accordance with ASC 718, Compensation – Stock Compensation Measurement Objective – Fair Value at Grant Date k. Leases The Company accounts for all leases in accordance with ASC 842, Leases l. Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position and cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2023
Going Concern [Abstract]
GOING CONCERN	NOTE 2 - GOING CONCERN The Company acknowledges that the funds on hand as of June 30, 2023, will not be sufficient to enable it to execute its business plan and funding through the sale of equity capital and short term related party and other shareholder loans in order to meet the planned expenditures for development, operations, and administrative cost over the next 12 months will be required. Planned expenditures are approximately $1,200,000 for the next twelve months. The Company is currently funded through September 30, 2023. If plans to obtain further financing prove to be insufficient to fund operations, continued viability could be at risk. These factors raise substantial doubt about the Company's ability to continue as a going concern.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment and related accumulated depreciation consisted of the following at June 30, 2023, and December 31, 2022: June 30, 2023 December 31, 2022 Computer and office equipment $ 83,893 $ 90,368 Accumulated depreciation (83,893) (90,368) Total Property and Equipment $                         - $                            - Depreciation expense for the six months ended June 30, 2023 and 2022 was $-0- and $2,232, respectively. The Company relocated its laboratory facilities to another location. At the time of the move it sold the laboratory hood to the leasee moving into that space for the amount of $3,000. The hood was fully depreciated and the Company recorded a gain on sale of $3,000 in 2022.

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2023
Preferred Stock [Abstract]
PREFERRED STOCK	NOTE 4 - PREFERRED STOCK On October 19, 2011, the Company filed Articles of Incorporation with the State of Utah so as to authorize 10,000,000 shares of preferred stock having a par value of $0.001 per share. No

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2023
Common Stock [Abstract]
COMMON STOCK	NOTE 5 - COMMON STOCK There are 90,000,000 shares of common stock with a par value of $0.001 authorized. At June 30, 2023 and December 31, 2022, there were 81,348,469 and 81,348,469 shares of common stock issued and outstanding, respectively. In September 2022, the Company issued 2,000,000 shares of restricted common stock to Mr. William Hayde as inducement for him to accept the position of President, Chief Executive Officer, Director and Chairman of the Board. Mr. Hayde has strong relationships with the investment banker community in New York and has closed a number of transactions.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6 - COMMITMENTS AND CONTINGENCIES Operating Lease Obligations The Company entered into a lease for office space in February 2017 for $950 per month. In November 2017 the Company signed a six-month extension of the lease with a lease payment of $978 per month. In March 2018 the Company extended the lease agreement through August 31, 2019 at a rate of $1,008 per month. In July 2019 the Company extended the lease agreement through August 31, 2020 at a rate of $1,038 per month, in August 2020 the Company extended the lease agreement through August 31, 2021 at a rate of $1,038 per month, and in August 2021 the Company extended the lease through August 31, 2022 at a rate of $1,059 per month. The lease was not extended when it terminated on August 31, 2022. Office space is currently rented at $1,000 per month on a month-to-month basis.

Employment Agreements

Employment Agreements	6 Months Ended
	Jun. 30, 2023
Employment Agreements [Abstract]
EMPLOYMENT AGREEMENTS	NOTE 7 – EMPLOYMENT AGREEMENTS Mr. Hayde and Mr. Merrell have received employment agreements. The agreements provide for no compensation until such time as a major funding event has been finalized, at which time the rate of compensation will be established by the Board of Directors. Mr. Hayde and Mr. Merrell are being provided $500 per month as reimbursement of office expenses.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS The Company has evaluated all other subsequent events pursuant to ASC Topic 855 and has determined that there are no events that require disclosure as of the date of issuance.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of Nu-Med Plus, Inc. (the “Company”). These financial statements are condensed and, therefore, do not include all disclosures normally required by accounting principles generally accepted in the United States of America. Therefore, these statements should be read in conjunction with the most recent annual consolidated financial statements of Nu-Med Plus, Inc. for the year ended December 31, 2022 included in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023. In particular, the Company’s significant accounting principles were presented as Note 1 to the Consolidated Financial Statements in that report. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying condensed consolidated financial statements and consist of only normal recurring adjustments. The results of operations presented in the accompanying condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023.
Revenue Recognition	b. Revenue Recognition The Financial Accounting Standards Board (“FSB”) issued new guidance for the recognizing and reporting of revenue in contracts with customers. The effective date for implementation for public companies was January 1, 2018. The new guidance established a five-step analysis to be followed when determining the recognition of revenue. 1. Identify the contract with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when, or as, the reporting organization satisfied a performance obligation. While the Company is an early-stage company with no revenue, at the time we begin to generate revenue the Company will recognize such revenue in conformity with the guidelines set forth by ASC 606.
Estimates	c. Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	d. Cash and Cash Equivalents The Company considers all deposit accounts and investment accounts with an original maturity of 90 days or less to be cash equivalents. The cash balance we currently have on deposit is within the limits for which the FDIC insures.
Property and Equipment	e. Property and Equipment Property and equipment is stated at cost. Expenditure for minor repairs, maintenance, and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. Expenditures, exceeding $500, for new assets or that increase the useful life of existing assets are capitalized. Depreciation is computed using the straight-line method. The lives over which the property and equipment are depreciated are five to seven years.
Fair Value Measurements	f. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB Accounting Standards Codification (“ASC”) Topic 820 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements), as follows: Level 1 - Quoted market prices in active markets for identical assets or liabilities; Level 2 - Inputs other than level one inputs that are either directly or indirectly observable; and Level 3 - Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. All cash, accounts payable and accrued liabilities are carried at cost, which approximates fair value due to the short-term nature of these financial instruments. Additionally, we measure certain financial instruments at fair value on a recurring basis.
Earnings per Share	g. Earnings per Share The computation of earnings per share of common stock is based on the weighted average number of shares outstanding during the period of the financial statement. The company included -0- and -0- shares subscribed but unissued in its calculation of basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022, respectively. Diluted earnings per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. As of June 30, 2023 and 2022 there were -0- and -0-, respectively, potential dilutive shares that needed to be considered as common share equivalents. As of June 30, 2023 and 2022 there were no dilutive shares and the basic and diluted calculation is the same. Had there been dilutive shares they would have been excluded from the calculation for diluted earnings per share as there was a net loss and their inclusion in the calculation would be anti-dilutive.
Concentrations and Credit Risk	h. Concentrations and Credit Risk -
Income Taxes	i. Income Taxes Deferred taxes are provided on an asset and liability approach whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Stock-based Compensation	j. Stock-based Compensation The Company, in accordance with ASC 718, Compensation – Stock Compensation Measurement Objective – Fair Value at Grant Date
Leases	k. Leases The Company accounts for all leases in accordance with ASC 842, Leases
Recent Accounting Pronouncements	l. Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position and cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment and related accumulated depreciation consisted of the following at June 30, 2023, and December 31, 2022: June 30, 2023 December 31, 2022 Computer and office equipment $ 83,893 $ 90,368 Accumulated depreciation (83,893) (90,368) Total Property and Equipment $                         - $                            -

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Summary of Significant Accounting Policies [Abstract]
Useful life of existing assets (in Dollars)			$ 500
Shares subscribed	0	0	0	0
Dilutive shares			0	0

Going Concern (Details)

Going Concern (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Going Concern [Abstract]
Planned expenditures	$ 1,200,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Property and Equipment [Abstract]
Depreciation expense	$ 0	$ 2,232
Lease amount of laboratory hood	$ 3,000
Gain on sale			$ 3,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Schedule of Property And Equipment [Abstract]
Computer and office equipment	$ 83,893	$ 90,368
Accumulated depreciation	(83,893)	(90,368)
Total Property and Equipment

Preferred Stock (Details)

Preferred Stock (Details) - $ / shares	Jun. 30, 2023	Dec. 31, 2022	Oct. 19, 2011
Preferred Stock [Abstract]
Preferred stock, share authorized	10,000,000	10,000,000	10,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, share outstanding

Common Stock (Details)

Common Stock (Details) - $ / shares	1 Months Ended
	Sep. 30, 2022	Jun. 30, 2023	Dec. 31, 2022
Common Stock (Details) [Line Items]
Common stock authorized		90,000,000	90,000,000
Common stock par value (in Dollars per share)		$ 0.001	$ 0.001
Common stock issued		81,348,469	81,348,469
Common stock outstanding		81,348,469	81,348,469
Mr. William Hayde [Member]
Common Stock (Details) [Line Items]
Shares of restricted common stock	2,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2023	Aug. 31, 2022	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2019	Nov. 30, 2017	Feb. 28, 2017
Commitments and Contingencies [Abstract]
Monthly office lease payment	$ 1,000	$ 1,059	$ 1,038	$ 1,038	$ 1,008	$ 978	$ 950

Employment Agreements (Details)

Employment Agreements (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Employment Agreements [Abstract]
Reimbursement of office expenses	$ 500